U-Neuron Biomedical (ROCO:6973) EBIT : NT$-61.00 Mil (TTM As of Jun. 2024)

U-Neuron Biomedical EBIT Chart

Competitive Comparison of U-Neuron Biomedical's EBIT

For the Biotechnology subindustry, U-Neuron Biomedical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

U-Neuron Biomedical's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, U-Neuron Biomedical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where U-Neuron Biomedical's EV-to-EBIT falls into.

U-Neuron Biomedical EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-61.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

U-Neuron Biomedical  (ROCO:6973) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

U-Neuron Biomedical's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

where

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

U-Neuron Biomedical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

where Working Capital is:

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

U-Neuron Biomedical's Earnings Yield (Joel Greenblatt) % for today is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

U-Neuron Biomedical EBIT Related Terms

Thank you for viewing the detailed overview of U-Neuron Biomedical's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

U-Neuron Biomedical Business Description